AHAxel Hofmann

Axel Hofmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Axel Hofmann has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Aryeh Shander

    Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Health, Englewood, New Jersey

    3 shared publications
  • Shannon Farmer

    2 shared publications
  • A. Shander

    Department of Anesthesiology and Critical Care and Hyperbaric Medicine; The Institute for the Patient Blood Management and Bloodless Medicine and Surgery at Englewood Hospital and Medical Center, Englewood, NJ, USA; Anesthesiology & Medicine at Mt. Sinai School of Medicine, New York City, NY, USA

    1 shared publication
  • Albert Farrugia

    University of Western Australia

    1 shared publication
  • Aryeh Shander

    Department of Anesthesiology, Critical Care, Englewood Health, Englewood, New Jersey; ASA Editorial Board for Perioperative Life Support (PeRLS)

    1 shared publication
  • Aryeh Shander

    Department of Anesthesiology, Critical Care and Hyperbaric Medicine, TeamHealth, Englewood Hospital, Englewood, New Jersey; Society for the Advancement of Patient Blood Management (SABM), Englewood, New Jersey

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)

    by Aryeh Shander, Howard L. Corwin, Jens Meier, Michael Auerbach, Elvira Bisbe, Jeanna Blitz, Jochen Erhard, David Faraoni, Shannon Dhsc Farmer, Steven M. Frank, et al.

    Background: Perioperative anemia has been associated with increased risk of red blood cell transfusion and increased morbidity and mortality after surgery. The optimal approach to the diagnosis and management of perioperative anemia is not fully established. Objective: To develop consensus recommendations for anemia management in surgical patients. Methods: An international expert panel reviewed the current evidence and developed recommendations using modified RAND Delphi methodology. Results: The panel recommends that all patients except those undergoing minor procedures be screened for anemia before surgery. Appropriate therapy for anemia should be guided by an accurate diagnosis of the etiology. The need to proceed with surgery in some patients with anemia is expected to persist. However, early identification and effective treatment of anemia has the potential to reduce the risks associated with surgery and improve clinical outcomes. As with preoperative anemia, postoperative anemia should be treated in the perioperative period. Conclusions: Early identification and effective treatment of anemia has the potential to improve clinical outcomes in surgical patients.


  • Patient Blood Management: Improving Outcomes for Millions While Saving Billions. What Is Holding It Up?

    by Axel Hofmann, Aryeh Shander, Neil Blumberg, Jeffrey M. Hamdorf, James P. Isbister, Irwin Gross

    Patient blood management (PBM) offers significantly improved outcomes for almost all medical and surgical patient populations, pregnant women, and individuals with micronutrient deficiencies, anemia, or bleeding. It holds enormous financial benefits for hospitals and payers, improves performance of health care providers, and supports public authorities to improve population health. Despite this extraordinary combination of benefits, PBM has hardly been noticed in the world of health care. In response, the World Health Organization (WHO) called for its 194 member states, in its recent Policy Brief, to act quickly and decidedly to adopt national PBM policies. To further support the WHO’s call to action, this article addresses 3 aspects in more detail. The first is the urgency from a health economic perspective. For many years, growth in health care spending has outpaced overall economic growth, particularly in aging societies. Due to competing economic needs, the continuation of disproportionate growth in health care spending is unsustainable. Therefore, the imperative for health care leaders and policy makers is not only to curb the current spending rate relative to the gross domestic product (GDP) but also to simultaneously improve productivity, quality, safety of patient care, and the health status of populations. Second, while PBM meets these requirements on an exceptional scale, uptake remains slow. Thus, it is vital to identify and understand the impediments to broad implementation. This includes systemic challenges such as the so-called “waste domains” of failure of care delivery caused by malfunctions of health care systems, failure of care coordination, overtreatment, and low-value care. Other impediments more specific to PBM are the misperception of PBM and deeply rooted cultural patterns. Third, understanding how the 3Es—evidence, economics, and ethics—can effectively be used to motivate relevant stakeholders to take on their respective roles and responsibilities and follow the urgent call to implement PBM as a standard of care.


  • Open Access

    Systematic reviews and meta-analyses comparing mortality in restrictive and liberal haemoglobin thresholds for red cell transfusion: an overview of systematic reviews

    by Kevin M. Trentino, Shannon L. Farmer, Michael F. Leahy, Frank M. Sanfilippo, James P. Isbister, Rhonda Mayberry, Axel Hofmann, Aryeh Shander, Craig French, Kevin Murray

    Background: There are no overviews of systematic reviews investigating haemoglobin thresholds for transfusion. This is important as the literature on transfusion thresholds has grown considerably in recent years. Our aim was to synthesise evidence from systematic reviews and meta-analyses of the effects of restrictive and liberal transfusion strategies on mortality. Methods: This was a systematic review of systematic reviews (overview). We searched MEDLINE, Embase, Web of Science Core Collection, PubMed, Google Scholar, and the Joanna Briggs Institute EBP Database, from 2008 to 2018. We included systematic reviews and meta-analyses of randomised controlled trials comparing mortality in patients assigned to red cell transfusion strategies based on haemoglobin thresholds. Two independent reviewers extracted data and assessed methodological quality. We assessed the methodological quality of included reviews using AMSTAR 2 and the quality of evidence pooled using an algorithm to assign GRADE levels. Results: We included 19 systematic reviews reporting 33 meta-analyses of mortality outcomes from 53 unique randomised controlled trials. Of the 33 meta-analyses, one was graded as high quality, 15 were moderate, and 17 were low. Of the meta-analyses presenting high- to moderate-quality evidence, 12 (75.0%) reported no statistically significant difference in mortality between restrictive and liberal transfusion groups and four (25.0%) reported significantly lower mortality for patients assigned to a restrictive transfusion strategy. We found few systematic reviews addressed clinical differences between included studies: variation was observed in haemoglobin threshold concentrations, the absolute between group difference in haemoglobin threshold concentration, time to randomisation (resulting in transfusions administered prior to randomisation), and transfusion dosing regimens. Conclusions: Meta-analyses graded as high to moderate quality indicate that in most patient populations no difference in mortality exists between patients assigned to a restrictive or liberal transfusion strategy. Trial registration: PROSPERO CRD42019120503


  • Economic considerations on transfusion medicine and patient blood management

    by Axel Hofmann, Sherri Ozawa, Albert Farrugia, Shannon L. Farmer, Aryeh Shander


  • Strategies to preempt and reduce the use of blood products

    by Axel Hofmann, Shannon Farmer, Simon C. Towler

    Evidence-based patient blood management (PBM) is aimed at achieving better patient outcomes by relying on a patient's own blood rather than on donor blood. This review covers the rationale behind PBM, the treatment modalities involved and the drivers to adopt PBM as a new standard of care. Transfusion rates vary significantly between comparable countries; they also vary between centers for matched patients in standardized elective surgical interventions. Preoperative anemia, perioperative blood loss and liberal transfusion triggers are the main predictors for transfusion and pose risks to the patient. PBM is mitigating these risks by optimizing the patient's native red cell mass, minimizing blood loss, optimizing the physiological reserve of anemia and preempting transfusions. A growing number of studies show that transfusion is associated in a dose-dependent relationship with increased morbidity, mortality and hospital length of stay. Evidence suggests that this relationship is not merely associative but causal. Furthermore, the over-ageing population of the developed world leads to a growing gap between supply and demand of blood, the safety of donor blood remains unpredictable and the cost of transfusion is much higher than previously estimated. High transfusion variability, adverse transfusion outcomes, limited evidence for the benefit of transfusion particularly in elective patients and high cost of transfusion are challenging the traditional transfusion paradigm. National and state-wide initiatives are underway in Australia to broadly implement PBM and PBM programs as a new and cost-effective standard of care in the public health system.


  • Open Access

    Five Drivers Shifting the Paradigm from Product-Focused Transfusion Practice to Patient Blood Management

    by Axel Hofmann, Shannon Farmer, Aryeh Shander

    The objective of this paper is to introduce clinicians and health care professionals to the concept of patient blood management (PBM) and to explain the difference between PBM and the concept of “appropriate use” of blood products. The five reasons why modern health systems need to shift from product-focused transfusion practice to PBM are also presented. These are: the aging population with a leveraged demand for blood products opposed to a shrinking donor base; the growing awareness that transfusion is a complex service involving many different cost centers within a hospital and representing a multiple of the blood product cost; the continuous effort to protect blood pools from known, new, or re-emerging pathogens while facing uncertainty over their potentially long silent carrier states; the emerging evidence that transfusion is an independent risk factor for adverse outcomes; and finally, a lack of evidence for benefit of transfusion for the vast majority of recipients.